Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

100%(5 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_1

17%

Ph phase_3

17%

Ph phase_4

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 3Large-scale testing

1(16.7%)

Phase 4Post-market surveillance

4(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (16.7%)

Phase 31 (16.7%)

Phase 44 (66.7%)

Trials by Status

completed583%

terminated117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

NCT00919867

completedphase_4

Clinical Trials (6)

Showing 6 of 6 trials

NCT00919867Phase 1

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Completed

NCT02675400Phase 4

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

Completed

NCT00733356Phase 4

The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading

Completed

NCT01000064Phase 3

Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits

Terminated

NCT00573534Phase 4

Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse

Completed

NCT00801229Phase 4

Effect of Vyvanse on Driving in Young Adults With ADHD

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6